Journal
JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 111, Issue 4, Pages 861-867Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.xphs.2021.11.008
Keywords
Monoclonal antibodies; High concentration; Viscosity; Aggregation; Protein engineering; Subcutaneous
Ask authors/readers for more resources
Although many subcutaneously delivered, high-concentration antibody formulations have been approved and widely used, formulation scientists still face challenges in developing new monoclonal antibody-based drugs. These challenges include pharmaceutical attributes, clinical performance, and patient experience. This commentary focuses on the obstacle of maximizing the dose of the drug during HCAF development.
Although many subcutaneously (s.c.) delivered, high-concentration antibody formulations (HCAF) have received regulatory approval and are widely used commercially, formulation scientists are still presented with many ongoing challenges during HCAF development with new mAb and mAb-based candidates. Depending on the specific physicochemical and biological properties of a particular mAb-based molecule, such challenges vary from pharmaceutical attributes e.g., stability, viscosity, manufacturability, to clinical performance e.g., bioavailability, immunogenicity, and finally to patient experience e.g., preference for s.c. vs. intravenous delivery and/or preferred interactions with health-care professionals. This commentary focuses on one key formulation obstacle encountered during HCAF development: how to maximize the dose of the drug? We examine methodologies for increasing the protein concentration, increasing the volume delivered, or combining both approaches together. We discuss commonly encountered hurdles, i.e., physical protein instability and solution volume limitations, and we provide recommendations to formulation scientists to facilitate their development of s.c. administered HCAF with new mAb-based product candidates.(c) 2021 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available